View in EDS HTML Full Text PDF Full Text

Investigation of PB1‐F2 Protein‐Derived Peptide Effects on Clinical Symptoms and Inflammatory Factors in an Animal Model of Multiple Sclerosis.

Saved in:
Bibliographic Details
Title: Investigation of PB1‐F2 Protein‐Derived Peptide Effects on Clinical Symptoms and Inflammatory Factors in an Animal Model of Multiple Sclerosis.
Authors: Khatami, Seyed Hossein1 (AUTHOR), Karima, Saeed2 (AUTHOR), Kondori, Bahman Jalali3 (AUTHOR), Sepandi, Mojtaba4 (AUTHOR), Jangravi, Zohreh1 (AUTHOR) jangvariz7@gmail.com
Source: Biotechnology & Applied Biochemistry. Dec2025, Vol. 72 Issue 6, p1835-1844. 10p.
Subjects: Multiple sclerosis, Inflammation, CNS demyelinating autoimmune diseases, Neuroprotective agents, NF-kappa B, Autoimmune diseases, Chemokines, Proteins
Abstract: Multiple sclerosis (MS) is an autoimmune condition affecting the central nervous system (CNS), resulting in immune‐mediated demyelination and neurodegeneration. The NF‐κB signaling pathway is pivotal in the inflammatory processes that drive MS pathogenesis. Recent research has underscored the therapeutic potential of peptides owing to their low immunogenicity, high specificity, and minimal side effects. PB1‐F2, a protein from the influenza virus, has shown the capacity to modulate inflammation by inhibiting the NF‐κB pathway. Synthetic peptides were designed on the basis of the C‐terminal region of PB1‐F2 and evaluated for their ability to suppress NF‐κB‐mediated inflammatory responses. Among these peptides, RZV8 emerged as the most potent peptide and was selected for further investigation. This study aimed to explore the therapeutic effects of the intraperitoneal administration of RZV8 in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Following EAE induction in female C57BL/6J mice, the animals were treated with RZV8. Various serum inflammatory mediators, motor functions, myelination, and inflammatory cell infiltration levels were then assessed. Our results demonstrated that RZV8 administration alleviated EAE clinical severity, reducing inflammation, demyelination, and gliosis in EAE mice. We propose that the therapeutic effects of RZV8 are primarily due to its neuroprotective and anti‐inflammatory properties. These results could offer new perspectives for treating neuroinflammatory diseases, such as MS, highlighting RZV8 as a potential therapeutic candidate. [ABSTRACT FROM AUTHOR]
Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: egs
DbLabel: Engineering Source
An: 189914840
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Investigation of PB1‐F2 Protein‐Derived Peptide Effects on Clinical Symptoms and Inflammatory Factors in an Animal Model of Multiple Sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Khatami%2C+Seyed+Hossein%22">Khatami, Seyed Hossein</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Karima%2C+Saeed%22">Karima, Saeed</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kondori%2C+Bahman+Jalali%22">Kondori, Bahman Jalali</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sepandi%2C+Mojtaba%22">Sepandi, Mojtaba</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jangravi%2C+Zohreh%22">Jangravi, Zohreh</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> jangvariz7@gmail.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Biotechnology+%26+Applied+Biochemistry%22">Biotechnology & Applied Biochemistry</searchLink>. Dec2025, Vol. 72 Issue 6, p1835-1844. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Inflammation%22">Inflammation</searchLink><br /><searchLink fieldCode="DE" term="%22CNS+demyelinating+autoimmune+diseases%22">CNS demyelinating autoimmune diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroprotective+agents%22">Neuroprotective agents</searchLink><br /><searchLink fieldCode="DE" term="%22NF-kappa+B%22">NF-kappa B</searchLink><br /><searchLink fieldCode="DE" term="%22Autoimmune+diseases%22">Autoimmune diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Chemokines%22">Chemokines</searchLink><br /><searchLink fieldCode="DE" term="%22Proteins%22">Proteins</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Multiple sclerosis (MS) is an autoimmune condition affecting the central nervous system (CNS), resulting in immune‐mediated demyelination and neurodegeneration. The NF‐κB signaling pathway is pivotal in the inflammatory processes that drive MS pathogenesis. Recent research has underscored the therapeutic potential of peptides owing to their low immunogenicity, high specificity, and minimal side effects. PB1‐F2, a protein from the influenza virus, has shown the capacity to modulate inflammation by inhibiting the NF‐κB pathway. Synthetic peptides were designed on the basis of the C‐terminal region of PB1‐F2 and evaluated for their ability to suppress NF‐κB‐mediated inflammatory responses. Among these peptides, RZV8 emerged as the most potent peptide and was selected for further investigation. This study aimed to explore the therapeutic effects of the intraperitoneal administration of RZV8 in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Following EAE induction in female C57BL/6J mice, the animals were treated with RZV8. Various serum inflammatory mediators, motor functions, myelination, and inflammatory cell infiltration levels were then assessed. Our results demonstrated that RZV8 administration alleviated EAE clinical severity, reducing inflammation, demyelination, and gliosis in EAE mice. We propose that the therapeutic effects of RZV8 are primarily due to its neuroprotective and anti‐inflammatory properties. These results could offer new perspectives for treating neuroinflammatory diseases, such as MS, highlighting RZV8 as a potential therapeutic candidate. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=189914840
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/bab.2790
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1835
    Subjects:
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Inflammation
        Type: general
      – SubjectFull: CNS demyelinating autoimmune diseases
        Type: general
      – SubjectFull: Neuroprotective agents
        Type: general
      – SubjectFull: NF-kappa B
        Type: general
      – SubjectFull: Autoimmune diseases
        Type: general
      – SubjectFull: Chemokines
        Type: general
      – SubjectFull: Proteins
        Type: general
    Titles:
      – TitleFull: Investigation of PB1‐F2 Protein‐Derived Peptide Effects on Clinical Symptoms and Inflammatory Factors in an Animal Model of Multiple Sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Khatami, Seyed Hossein
      – PersonEntity:
          Name:
            NameFull: Karima, Saeed
      – PersonEntity:
          Name:
            NameFull: Kondori, Bahman Jalali
      – PersonEntity:
          Name:
            NameFull: Sepandi, Mojtaba
      – PersonEntity:
          Name:
            NameFull: Jangravi, Zohreh
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 08854513
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Biotechnology & Applied Biochemistry
              Type: main
ResultId 1